Immatics N.V.

NASDAQ:IMTX

Biotechnology

Healthcare
$6.10 +1.58%

+$0.15 today

Market cap
$912.78M
Beta
1.30
P/E (TTM)
-5.3
EPS (TTM)
-$1.59
52W Low $5.05High $12.41

Volume 1.57M

Average 0.46M

IMTX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Immatics N.V.NASDAQ: IMTX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of €58.76M (cash outflow) rose 47.4% year over year, behind the +906.0% change in trailing-twelve-month net income. Sequentially, it rose 66.2% from the prior quarter.

Context

  • Net income amounted to 390.9% of revenue in FY2025, up 381.2 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -€247.89M (+31.4%) for the fiscal year ending Dec 2026, a step up from the -1339.9% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-€58.76M+66.2% QoQ
Last fiscal yearDec 2025
-€188.69M-1339.9% YoY
LTMMar 2026
-€217.14M+906.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+47.4%-1.6%-49.0 pp
1 year-1339.9%+31.4%+1371.3 pp
3-year CAGR—+8.4%—
5-year CAGR-21.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the cash flow

Latest · FY2025
(188.69M) EUR
Year-over-year change
-1339.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How IMTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +906.0% is the highest of 11, against a peer median of +2.8%.
  • Net income amounts to 582.2% of revenue for IMTX, versus a peer median of 96.7%.
IMTX Competitors
Net Income for IMTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€1.71B EUR+348.2%—64.7%
LYELLyell Immunopharma, Inc.LTM Mar 2026$246.41M USD-26.3%+14.4%794858.1%
IMTXImmatics N.V.LTM Mar 2026€217.14M EUR+906.0%—582.2%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$173.76M USD-31.1%-16.9%—
TCRXTScan Therapeutics, Inc.LTM Mar 2026$124.31M USD-5.5%+25.1%1360.6%
JANXJanux Therapeutics, Inc.LTM Mar 2026$114.48M USD+47.3%+21.7%529.7%
CLLSCellectis S.A.LTM Mar 2026$67.27M USD+11.1%-11.8%98.8%
DTILPrecision BioSciences, Inc.LTM Mar 2026$43.6M USD+98.3%-25.7%96.7%
IMCRImmunocore Holdings plcLTM Mar 2026$27.59M USD+28.8%-20.5%7.2%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$9.47M USD-39.5%—40.9%
LEGNLegend Biotech CorporationLTM Sep 2026$2.81M USD-98.7%-12.6%0.2%
Peer median (excluding IMTX) —+2.8%-12.2%96.7%

Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(93.34M)37.51M(94.65M)15.22M(188.69M)
Depreciation & Amortization5.26M6.97M7.23M12.23M11.91M
Deferred Income Tax11.15M4.52M06.13M0
Stock-Based Compensation26.4M22.57M20.71M17.64M0
Change in Working Capital(31.7M)37.26M81.63M(163.88M)(42.23M)
Accounts Receivables569K(429K)(2.98M)(1.76M)(232.45K)
Inventory00(84.24M)00
Accounts Payables(31.78M)45.56M84.24M0(36.13M)
Other Working Capital(483K)(7.87M)84.61M(162.11M)(5.87M)
Other Non-Cash Items433K(8.7M)3.31M(45.37M)49.36M
Operating Cash Flow(81.78M)100.13M18.23M(158.03M)(169.66M)
Capital Expenditures(5.66M)(6.22M)(30.96M)(16.48M)(6.3M)
Acquisitions (Net)551K(199.91M)000
Purchases of Investments(11.3M)(216.32M)(415.33M)(450.35M)(324.92M)
Sales of Investments24.45M12.7M414.74M314.44M528.16M
Other Investing Activities(551K)199.96M(8K)(206K)0
Investing Cash Flow7.49M(209.79M)(31.39M)(152.39M)196.7M
Debt Repayment(2.71M)(2.84M)(3.85M)(2.01M)0
Common Stock Issued94K134.48M90.4M343.01M96.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(7.93M)(2.04M)(21.31M)(2.84M)
Financing Cash Flow(2.61M)123.71M84.52M319.68M93.51M
Effect of Forex Changes2.37M1.48M(1.4M)9.01M16.56M
Net Change in Cash(74.54M)15.53M69.95M18.28M137.12M
Free Cash Flow(87.44M)93.92M(12.73M)(174.51M)(175.95M)

Immatics N.V.

NASDAQ:IMTX

Intrinsic Alpha fair value

Locked

Current Price

$6.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.